A metabolomic approach to identifying biomarkers in blood of Alzheimer's disease.

ABSTRACT: Objective:This study aims to identify metabolites with altered levels of expression in patients with early and progressive stages of Alzheimer's disease (AD). Methods:All participants of the study underwent genetic screening and were diagnosed using both neuropsychological assessment and amyloid imaging before metabolome analysis. According to these assessments, the patients were classified as normal (n = 15), with mild cognitive impairment (n = 10), and with AD (n = 15). Results:Using a targeted metabolomic approach, we found that plasma levels of C3, C5, and C5-DC acylcarnitines, arginine, phenylalanine, creatinine, symmetric dimethylarginine (SDMA) and phosphatidylcholine ae C38:2 were significantly altered in patients with early and progressive stages of AD. We created a predictive mod

SUBMITTER: Lin CN 

PROVIDER: S-EPMC6414491 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature